RxDoctor Payments DataLook up a doctor →

Amparo Gutierrez, MD

Neuromuscular Medicine · Orlando, FLNPI 1225051170

Payments from drug & device makers

$4,568,815in general payments, 2019–2025

Across 2,013 payments — averaging $2269.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3.3M
  • Sanofi$423K
  • EMD Serono, Inc.$348K
  • Biogen$327K
  • TG Therapeutics, Inc.$79K
  • E.r. Squibb & Sons, L.L.C.$29K
  • plus $98K from 54 others
$314in research payments, 2019–2025

Across 6 payments — averaging $52.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$237
  • Novartis Pharma AG$77

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis310$3,266,640
Sanofi168$422,800
EMD Serono, Inc.313$347,505
Biogen311$327,129
TG Therapeutics, Inc.86$78,596
E.r. Squibb & Sons, L.L.C.27$28,588
Ares Trading SA5$21,393
Amgen(2 entities)78$19,770
Genentech USA, Inc.157$15,815
Johnson & Johnson(2 entities)31$12,425
AbbVie(2 entities)85$10,621
Bristol Myers Squibb89$3,974
AstraZeneca(2 entities)65$2,708
Banner Life Sciences, LLC27$1,795
Janssen Scientific Affairs, LLC2$1,760
Argenx US, Inc.18$1,083
Pfizer23$753
ANI Pharmaceuticals, Inc.7$513
Teva Pharmaceuticals USA, Inc.31$368
Genentech, Inc.4$345
Tanabe Pharma America, Inc.17$307
Biohaven Pharmaceuticals, Inc.9$275
Catalyst Pharmaceuticals, Inc.6$246
UCB, Inc.10$230
Neurelis, Inc.8$218
Grifols USA, LLC5$212
Acadia Pharmaceuticals Inc10$210
Amylyx Pharmaceuticals, Inc.4$182
Sanofi-aventis U.S. LLC4$169
Vanda Pharmaceuticals Inc.15$162
Otsuka America Pharmaceutical, Inc.8$157
EDW Pharma, Inc.2$145
Eisai Inc.2$139
Axsome Therapeutics, Inc.6$123
Lundbeck LLC5$121
Lilly USA, LLC8$120
Takeda Pharmaceuticals U.S.A., Inc.4$110
Mallinckrodt Hospital Products Inc.3$99
CSL Behring4$95
Mallinckrodt Enterprises LLC5$92
Biohaven Pharmaceutical Holding Company Ltd.4$89
Acorda Therapeutics, Inc4$76
Scilex Pharmaceuticals Inc.4$70
Xeris Pharmaceuticals, Inc.3$67
SK Life Science, Inc.3$64
Neurocrine Biosciences, Inc.2$50
Avanir Pharmaceuticals, Inc.3$48
Coloplast1$48
Mylan Specialty L.p.2$42
Alnylam Pharmaceuticals Inc.1$29
Strongbridge US Inc.2$29
Cycle Pharmaceuticals Inc2$28
Merz Pharmaceuticals, LLC1$25
GE HealthCare1$21
Livanova USA, Inc.1$20
Sumitomo Pharma America, Inc.1$20
ITF Therapeutics LLC1$19
Amneal Pharmaceuticals LLC1$17
Idorsia Pharmaceuticals US Inc1$17
Bayer1$15

How this compares

Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$68,722
Medicare patients
196
Services billed
3,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromuscular medicine in Orlando

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →